Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Countries may need to "give up" swine flu vaccine to most vulnerable countries, reveals new research

19.10.2009
* Countries should be prepared to sacrifice their vaccines in a coordinated fashion - it might be in their best interests
* Lack of centralized, global coordination to contain the spread of infection may result in significantly greater infections

As countries begin stockpiling swine flu vaccines to deal with an anticipated "second wave" outbreak, research from the European School of Management & Technology (ESMT) in Berlin and Duke University in North Carolina warns that countries should be prepared to sacrifice their vaccines to more vulnerable countries in the face of a critical outbreak.

The research suggests that this may prove the best method of minimizing the total number of people infected globally and containing the spread of the disease across geographies.

The study uses a sophisticated mathematical model that represents the dynamics of an epidemic taking hold, factoring in the character of initial infections, the spread of the disease and drug efficacy. Using economic 'game theory', the research models how countries with drug supplies should respond to an epidemic in a neighboring country with little or no supplies of their own, when the objective is to protect their respective populations.

While accepting the political cost of sacrificing supplies to other nations, the research concludes that at the very least some countries will have to face up to the reality of giving up all their drug stockpiles to contain the pandemic globally. The ideal solution would be centralized decision-making and deployment of drugs, by an agency such as the World Health Organization (WHO). In this area, the study highlights the fundamental tension that world governments will face in effectively combating a global outbreak: the current lack of centralized control.

The research concludes that having a centralized planner take ownership and allocate drugs to the country first affected by outbreak would result in the best global containment of infection, and typically benefit all countries including those giving up drugs. Yet as richer nations begin to stockpile vaccines to deal with a national outbreak, the reality is that individual nations will be faced with the decentralized decision about whether or not to give away their supplies.

To be effective all countries will need to be prepared to give up their supplies, as only one or two nations' sacrifice would be futile. Moreover, the likelihood is that decentralized decision-making will leave countries locked in a 'prisoner's dilemma' - watching one another's actions, where no-one is prepared to make the first move. The research's modeling shows that only in half of these cases would individual countries reach the same decision as a central planner, resulting in around double the number of global infections than if centralized co-ordination were possible.

Francis de Véricourt, Professor at the European School of Management & Technology, explains: "Drug allocation will not be as effective when the decision-makers are individual governments, which in turn will dramatically increase the chance of infection from abroad. What is needed is for nations to come together and agree a shared drug allocation strategy. In reality, this is in their 'selfish' best interest as it will result in the best chance of arresting the spread of the disease including, potentially, to their own shores. Nonetheless, the political risk of sacrificing vaccines is clearly enormous. The inefficiency of decentralized action is not necessarily about free-riding off the generosity of another state - it is the very real and difficult decision facing political leaders about how best to act."

Recent events have shown that some progress is being made towards more centralized thinking, with nine countries (including the US and UK) pledging to give up 10 per cent of their supplies to help fight the spread of infection internationally. At present, the majority of drugs have been purchased by richer nations considered at less risk, with most vaccines being produced in Western Europe, North America and Japan. However, the UN has called for much greater donation, claiming that £900m needs to be raised to help poorer nations fight the onset of a global epidemic that could kill millions. According to flucount.org, the number of reported H1N1 infections now stands at 473,774 across the globe. At the start of this week, the site reported that 352 people had died from H1N1 deaths in the previous seven days - an increase of 9.3% on the previous week.

Francis de Véricourt concludes:
"The outcome of our study is clearly disturbing because while it is apparent that centralized drug allocation is the best solution worldwide, it can sometimes result in significant discrepancies between nations. Where the central planner's drug allocation typically benefits all countries, our research still highlights circumstances where a centralized decision would hurt some drug-possessing countries. Certain countries stand to benefit considerably while others could actually suffer a greater number of infections, or worse fatalities, than if they had acted purely in their own interests and hoarded their supplies. This is a global crisis which requires some global thinking. A common objective is critical."
Should you wish to speak to Francis de Véricourt, or find out more information about the study, please contact:
Contact
Kristin Dolgner
Tel.: +49 (0)30 21231-1066
kristin.dolgner@esmt.org
Martha Ihlbrock
Tel.: +49 (0)30 21231-1043
martha.ihlbrock@esmt.org
About ESMT
ESMT European School of Management and Technology was founded in October 2002 by 25 leading global companies and institutions. The international business school offers Full-time MBA and Executive MBA programs, as well as executive education in the form of open enrollment and customized programs. The School also features in-house research-oriented consulting services in the areas of competition and regulation. ESMT is a private university based in Berlin, Germany, with an additional location in Schloss Gracht near Cologne.

Martha Ihlbrock | idw
Further information:
http://www.esmt.org

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Electrode materials from the microwave oven

19.10.2017 | Materials Sciences

New material for digital memories of the future

19.10.2017 | Materials Sciences

Physics boosts artificial intelligence methods

19.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>